A Pink Sheet infographic shows how insulins account for the largest category of transition products, with 27 NDAs that will be "deemed" BLAs in six months; agency is working on a policy to address the transition of authorized generic insulins to regulation under the PHS Act, Office of Therapeutic Biologics And Biosimilars acting policy director Eva Temkin says.
With just six months to go before dozens of protein products originally approved as drugs magically turn into biologics, the US Food and Drug Administration is providing more clarity on the identity of the affected applications.
On 24 September, the agency issued an updated, preliminary list of 91 new drug applications approved under the Food,...